Loading
A phase 3 trial testing QLC5508 in non-small-cell lung cancer, now recruiting.
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06954246, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Open-label Study of MHB088C for Injection Versus Treatment of Physician's Choice (TPC) in Comparing the Efficacy and Safety in Subjects With Relapsed Small Cell Lung Cancer (SCLC). Planned enrolment is 450 participants (estimated). The study started in 2025-06-04 and primary completion is expected in 2027-05. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/